Second-Generation Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response: A Systematic Review and a Meta-Analysis

The treatment with 2nd-generation tyrosine kinase inhibitors (2G-TKIs), namely, dasatinib and nilotinib, has been reported to have faster and deeper responses in newly diagnosed chronic phase-chronic myeloid leukemia (CP-CML) patients as compared with imatinab. A number of studies on the discontinua...

Descripción completa

Detalles Bibliográficos
Autores principales: Di, Qiongnan, Deng, Huiyang, Zhao, Yingxin, Li, Bo-ya, Qin, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702334/
https://www.ncbi.nlm.nih.gov/pubmed/34956393
http://dx.doi.org/10.1155/2021/3110622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702334/
https://www.ncbi.nlm.nih.gov/pubmed/34956393
http://dx.doi.org/10.1155/2021/3110622

Ejemplares similares